However, it is worth noting that only patients with tumors overexpressing c-Met can benefit from HGF/c-Met targeting therapy, as these interventions inhibit typical c-Met-associated processes such as oncogenesis, cancer metastasis, and drug resistance [40]. Here, HGF is linked to cancer.